

Certificate of Analysis

TTK, active (Recombinant enzyme expressed in Sf21 insect cells)

Item # 15-014, 15-014-K, 15-014M

Parent Lot # 226345

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal GST tagged, recombinant, human TTK full length, expressed by baculovirus in Sf21 insect cells. Purified using glutathione agarose.
 Purity 64% by SDS-PAGE and Coomassie blue staining. MW = 124 kDa.

Specific Activity (Parent lot# 226345): 54 U/mg, where one unit of TTK activity is defined as 1 nmol phosphate incorporated into 0.33 mg/ml myelin basic protein per minute at 30°C with a final ATP concentration of 100 µM.

Formulation: 0.60 mg/ml of enzyme in 50 mM Tris/HCl pH 8.0, 4 mM glutathione, 266 mM NaCl, 0.09 mM EGTA, 0.03% Brij-35, 270 mM sucrose, 0.9 mM benzamidine, 0.2 mM PMSF, 0.09% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
 NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 35–750 ng of this lot of enzyme phosphorylated 0.33 mg/ml myelin basic protein in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as TTK with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 5 x Reaction Buffer:** 40 mM MOPS/NaOH pH 7.0, 1 mM EDTA.
- 2. Myelin basic protein:** Use at a final assay concentration of 0.33 mg/ml. Prepare a 3.33 mg/ml stock and add 2.5 µl of stock per assay point.
- 3. TTK, active:** Dilute with 20 mM MOPS/NaOH pH 7.0, 1 mM EDTA, 0.01% Brij-3 5, 5% glycerol, 0.1% 2-mercaptoethanol, 1 mg/ml BSA. Use 35–750 ng per assay point.
- 4. [γ -³³P]ATP:** 2.5 x MgAc/[γ -³³P]ATP cocktail: 25 mM MgAc and 0.25 mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 – 800 cpm/pmol as required).

Assay Procedure (96 well plate format):

1. Add 5 µl of 5 x reaction buffer per assay to wells.
2. Add 2.5 µl of MBP.
3. Add **2.5 µl (35–750 ng) TTK, active.**
4. Add 5 µl of dH₂O.
5. Add 10 µl of diluted [γ -³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 µl of 3% phosphoric acid.
8. Transfer a 10 µl aliquot onto the appropriate area of a **P30 Filtermat.**
9. Wash the filtermat three times for 5 minutes with 75 mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the dried filtermat to a sealable plastic bag and add 4 ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 µl of 30% phosphoric acid.

Certificate of Analysis

TTK, active Sequence Information

Protein	Human TTK
Tags	N-terminal GST
Native sequence	M233 of the recombinant protein is equivalent to M1 of human TTK
Accession number	GenBank NM_003318.3 The recombinant protein contains the amino acid substitution S389A with reference to GenBank NM_003318.3. S389A is reported in GenBank M86699.1. The DNA sequence is partially codon optimized for expression purposes and therefore contains non-translational nucleotide base differences with respect to GenBank NM_003318.3.

Recombinant TTK amino acid sequence:

```

1  MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID
61  GDVKLTQSMa IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV
121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK
181 KRIEAI PQID KYLKSSKYIA WPLQGQWATF GGGDHPPKSD LVPRGSKEFG RRMESEDLSG
241 RELTIDSIMN KVRDIKNKFK NEDLTDELSL NKISADTTDN SGTVNQIMMM ANNPEDWLSL
301 LLKLEKNSVP LSDALLNKLI GRYSQAIEAL PPDKYGQNES FARIQVRFAE LKAIQEPDDA
361 RDYFQMARAN CKKFAFVHIS FAQFELSQGN VKKSKQLLQK AVERGAVPLE MLEIALRNLN
421 LQKKQLLSEE EKKNLSASTV LTAQESFSGS LGHLQNRNNS CDSRGQTTKA RFLYGENMPP
481 QDAEIGYRNS LRQTNKTKQS CPFGRVPVNL LNSPDCDVKT DDSVVPFCFMK RQTSRSECRD
541 LVVPGSKPSG NDSCELRNLK SVQNSHFKEP LVSDEKSEL IITDSITLKN KTESSLLAKL
601 EETKEYQEPE VPESNQKQWQ AKRKSECINQ NPAASSNHWQ IPELARKVNT EQKHTTFEQP
661 VFSVSKQSPS ISTSKWFDPK SICKTPSSNT LDDYMSCFRT PVVKNDFPPA CQLSTPYGQP
721 ACFQQQQHQI LATPLQNLQV LASSSANECI SVKGRIYSIL KQIGSGGSSK VFQVLNEKKQ
781 IYAIKYVNLE EADNQTLDSY RNEIAYLNKL QQHSCKIIRL YDYEITDQYI YMVMECGNID
841 LNSWLKKKKS IDPWERKSYW KNMLEAVHTI HQHGIVHSDL KPANFLIVDG MLKLIDFGIA
901 NQMOPDPTTSV VKDSQVGTVN YMPPEAIKDM SSSRENGKSK SKISPKSDVW SLGCILYYMT
961 YGKTPFQQII NQISKLHAI I DPNHEIEFPD IPEKDLQDVL KCCLKRDPKQ RISIPELLAH
1021 PYVQIQTHPV NQMAKGTTEE MKYVLGQLVG LNSPNSILKA AKTLYEHYSG GESHNSSSSK
1081 TFEKKRGKK
  
```

Recombinant TTK nucleotide sequence:

```

1  atgtccccta tactaggtta ttggaataatt aagggccttg tgcaaccacac tcgacttctt
61  ttggaatatc ttgaagaaaa atatgaagag catttgatag agcgcgatga aggtgataaa
121 tggcgaaaca aaaagtttga attgggtttg gagtttccca atcttcctta ttatattgat
181 ggtgatgtta aattaacaca gtctatggcc atcatagctt atatagctga caagcacaac
241 atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcggttttg
301 gatattagat acggtgtttc gagaattgca tataagtaaag actttgaaac tctcaaagtt
361 gattttctta gcaagctacc tgaaatgctg aaaatgttcg aagatcgttt atgtcataaa
421 acatatatta atggtgatca tgtaacccat cctgacttca tgttgatga cgctcttgat
481 gttgttttat acatggaccc aatgtgcctg gatgcgttcc caaaattagt ttgttttaaa
541 aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gatatagca
601 tggccttttg agggctggca agccacgttt ggtgggtggcg accatcctcc aaaatcggat
661 ctggttccgc gtggatccaa ggaattcggg cgacgaatgg aatctgaaga tctgtctgga
721 agagagttga caatcgactc cattatgaac aaggtgaggg atattaagaa caaatttaag
781 aacgaggact tgaccgacga actgtccttg aacaagatta gcgctgatac cacagacaac
841 tccggaactg tgaaccagat tatgatgatg gcaaacaacc ccgaagactg gctgagcttg
  
```

Certificate of Analysis

```

901 ctccctcaagc tggagaaaaa ctccgttccct ctgagcgatg ctctgttgaa taagctgata
961 ggcaggctact cccaggctat cgaggctctg ccaccagata aatacgggtca gaacgagtc
1021 tttgccagga ttcaagtgcg cttcgccgag ctgaaagcta tccaggagcc cgacgatgcc
1081 cgcgactact ttcagatggc tcgcgcaaac tgcaagaagt tcgcctttgt gcacattagc
1141 tttgccaggt ttgaactgtc tcagggaaac gtcaagaaat ccaagcaact gctgcagaaa
1201 gccgtggaac gcggtgcagt ccctctcgag atgctggaga tcgctctcag gaatctgaac
1261 ctgcaaaaaga agcaactgct ctcaaggaa gagaagaaaa acctctctgc ttccactgtg
1321 ttgaccgccc aggagtcctt ttccggctcc ctcgcccatc tccaaaacag aaacaattct
1381 tgtgattcac gcggtcaaac aaccaaggcc agattcttgt acggtgagaa tatgccccca
1441 caagatgctg aaatcggtc taggaactca ctcaggcaga ctaacaaaac aaagcaatct
1501 tgccccttcg gcagggtgcc cgtaaatctg ctcaattcac ccgactgcga cgtcaagacc
1561 gacgactccg ttgtgccatg tttcatgaag aggcaaacct cacgctccga gtgcccgcg
1621 ctggtggttc caggatcaaa gccctcagga aatgattctt gcgagctcag gaatctcaag
1681 agcgtgcaga atagccactt taaggagcca ctggtttctg atgagaaaag ctcagagctc
1741 atcatcaccg actctattac tctgaagaat aagaccgaga gctcactctt ggccaagctg
1801 gaagaaacaa aggagtatca ggaaccagaa gttcctgagt ccaacaaaaa gcagtggcaa
1861 gctaagcgca agtccgagtg tatcaatcag aacctgccc ctagctccaa tcattggcaa
1921 atccccgagt tggccaggaa agtgaataca gaacagaaac acaccacatt cgagcaacct
1981 gtttttagcg tgtccaagca gtctctctcc atctccacct caaagtgggt tgacccaaaa
2041 tctatctgta agacaccctc cagcaacct ctggatgatt acatgagctg ttttagaact
2101 ccagtgggtg agaattgatt cccaccgcga tgtcaactct ctacacccta cggccagccc
2161 gcatgtttcc aacaacaaca acaccaaata ctggctaccc cactgcaaaa tctccaggtc
2221 ctggcttccct cctcagctaa tgagtgcatt tcagttaagg gcaggatcta cagcattttg
2281 aagcaaattg gatcaggcgg ctcaagcaag gtcttccagg tgctgaatga gaagaaacag
2341 atctacgcaa ttaagtacgt gaacctggaa gaggcgata accagacact ggactcatac
2401 aggaacgaaa tcgcctatct gaacaagctg cagcagcatt ctgacaaaat catcaggctg
2461 tacgactatg agatcactga ccagtacatc tacatggtca tggagtgtgg caatatcgac
2521 ttgaatagct ggctgaagaa gaaaaagtca atcgaccctt gggagaggaa gtcctactgg
2581 aaaaacatgc tcgaggctgt gcacactatt catcaacacg gtattgtcca ttccgacctg
2641 aaacctgcc aacttctgat cgtcgatggc atgctgaagc tcattgattt cgggaattgct
2701 aatcaaattg agcctgacac tacatccgtc gttaaagact ctcaagtggg aaccgtgaat
2761 tatatgcccc cagaggccat caaagacatg tcctcatccc gcgaaaacgg caagtccaag
2821 tccaaaattt cccccaatc agacgtgtgg tcaactcgat aaccagatca gcaagttgca cgctattatc
2881 tacggcaaga ctccctttca gcagatcatc aaccagatca gcaagttgca cgctattatc
2941 gatcctaacc acgagattga gttccccgat attcctgaaa aggatttgca ggatgtcctc
3001 aagtgttgcc tgaagagaga tccaagcag cgcatttcaa tccctgagct gctcgctcac
3061 ccttacgtgc agatccaaac ccatcccgtg aaccaaattg ccaaaggaa tacagaggag
3121 atgaaatagc ttctgggtca gctggctggc ctgaactccc ccaactccat tttgaaagcc
3181 gccaagactc tgtacgagca ctattctggt ggcgagtcac ataacagcag ctctccaag
3241 acattcgaga agaagagggg aaagaagtga
  
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.